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BRIEF COMMUNICATION
Among the approximately 400 snakebites reported
annually in Taiwan, snake envenomation is a com-
mon medical emergency.1 Recent hospital-based
studies showed that Taiwan habu (Protobothrops
mucrosquamatus, formerly known as Trimeresurus
mucrosquamatus) and green habu (Trimeresurus stej-
negeri stejnegeri) accounted for the majority of 
venomous snakebites in northern Taiwan.2,3 The
Taiwan habu and green habu are from the crotaline
(pit viper) subfamily, mainly producing the hem-
orrhagic type of venoms.4
Antivenom is the mainstay therapy for cro-
taline snakebites.5 In Taiwan, a pepsin-digested
F(ab’)2 fragment, bivalent antivenom produced
from equine serum has been marketed by the
National Institute of Preventive Medicine to treat
crotaline snakebites since 1986. Based on labo-
ratory neutralization studies and empirical expe-
rience, the Taiwan Poison Control Center (PCC)
recommends the use of one vial of antivenom
every 2 hours until clinical manifestations sta-
bilize, or a total of four vials of antivenom.6
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However, the efficacy of the above approach re-
mains undefined. In the absence of evidence-based
guidelines, clinical toxicologists and other spe-
cialists (e.g. surgeons and emergency physicians)
have adopted somewhat different approaches 
on antivenom therapy. In the study hospital, 
a major medical center in northern Taiwan, clini-
cal toxicologists (medical group) follow the PCC
guidelines, while surgeons (surgical group) tend
to use higher doses of antivenom because they
believe that more antivenom may be beneficial.7
As a rule, both groups administered one vial of
antivenom to snake-envenomed patients on ini-
tial presentation. Antivenom was then given in
increments of one vial every 2 hours by toxicolo-
gists and two vials every 2 hours by surgeons
until symptoms completely ceased to progress.
The total dosage in the medical group was up to
four vials according to PCC guidelines, but was
unlimited in the surgical group.
Antivenom can neutralize crotaline snake
venoms and reduce complication and mortality
rates.2,5,8,9 However, the limited data available
on neurotoxic and Bothrops snake envenoming
suggest that a higher dose of antivenom may not
necessarily provide a better clinical outcome.7,10
No previous study has evaluated the effects of
the PCC-recommended approach versus an alter-
native antivenom regimen in treating crotaline
snakebites. We investigated the differences in
clinical outcomes between patients who received
antivenom according to the PCC approach and
patients who received antivenom according to 
a different therapeutic approach.
Methods
We conducted a retrospective cohort study by re-
viewing the medical records of patients with cro-
taline snakebite who were admitted to the study
hospital from 1991 through 2005. The study pro-
tocol was approved by the hospital’s institu-
tional review board. All patients were followed
from the time of envenomation till the date of
discharge, complete recovery, having permanent
sequelae, or envenomation-related death, which-
ever came last.
In the study hospital, patients with snakebite
were admitted to either the medical (clinical tox-
icology) ward or surgical ward after initial man-
agement in the emergency department. Ward
assignment for a patient depended on which team
was on duty and did not take into account the pa-
tient’s clinical condition. We excluded 49 patients
with non-crotaline snakebites (from Naja naja atra,
Bungarus multicinctus, Deinagkistrodon acutus, and
Daboia russelli siamensis) and 21 patients who were
bitten by unidentifiable snakes. The species of
culprit snake was documented through identifi-
cation of the snake brought in by the patient or
recognition of the snake’s picture by the patient.
Two authors (YCC and CCY) independently re-
trieved the following information from the med-
ical records: patients’ age, gender, comorbidities,
details of envenomation, clinical manifestations,
laboratory data, treatments, clinical outcomes,
complications, and length of hospital stay. Severity
of envenomation was classified into mild, mod-
erate, severe and very severe based on the num-
ber of swollen limb segments (one to three) and
whether systemic effects were present.11 Any dis-
pute regarding data retrieval was resolved by the
entire research team.
We considered the World Health Organiza-
tion’s guidelines for the clinical management of
snakebites in the Southeast Asian region in the
classification of clinical syndromes and com-
plications of snake envenomation.12 Definitions
of various complications were as follows: (1)
life-threatening complications, including severe
rhabdomyolysis (creatine phosphokinase, CK, 
> 10,000 U/L)13 and acute renal failure (creatinine
> 3.0 mg/dL and oliguria);8,9 (2) other com-
plications, consisting of systemic complications 
(coagulopathy—prothrombin time with Interna-
tional Normalized Ratio > 1.25, rhabdomyoly-
sis—CK > 1000 U/L and ≤ 10,000 U/L, and acute
renal impairment—creatinine > 1.4 mg/dL and
≤ 3.0 mg/dL)14 and local complications (cellulitis,
necrosis, compartment syndrome of bitten sites);
(3) surgical treatment, including debridement,
Antivenom therapy for crotaline snakebites
J Formos Med Assoc | 2007 • Vol 106 • No 12 1059
dermatomy, fasciotomy, and skin graft; (4) per-
manent sequelae, defined as digit or limb ampu-
tation; (5) adverse effects of antivenom, i.e.
presence of febrile and anaphylactoid reactions
that immediately developed after antivenom ther-
apy, and serum sickness. The primary outcome of
study interest was any life-threatening complica-
tions; secondary outcomes included other com-
plications. In the analysis of various outcomes, we
also evaluated the potential confounding effects 
of major comorbidities (e.g. diabetes mellitus),
transfer from other hospitals/clinics, prehospital
management (e.g. use of tourniquet or wound
incision), calendar year of envenomation, sites of
the snakebites, route of antivenom use (either local
plus intravenous injection or intravenous injec-
tion only), severity of envenomation, timing of
initial antivenom therapy, and use of antibiotics.
We employed the t and χ2 tests to compare 
intergroup differences in baseline characteristics
and various outcomes. Possible secular trend of
dose and initiation time of antivenom therapy
was tested by ANOVA. We then used univariate
and multivariate logistic regressions to estimate
the crude and adjusted odds ratio (OR) of devel-
oping clinical outcomes by using patients in the
medical group as the reference group. All analyses
were performed using SPSS version 10.0 (SPSS Inc.,
Chicago, IL, USA). ORs are presented with point
estimates and relevant 95% confidence intervals.
All p values are two-sided.
Results
There were 249 inpatients whose records were avai-
lable for review. After the application of various
exclusion criteria, a total of 179 patients, includ-
ing 136 patients with Taiwan habu envenomation
and 43 patients with green habu envenomation,
were eligible for study. The overwhelming major-
ity (90%) of patients received antivenom therapy
within 8 hours after being bitten. One-way
ANOVA did not find any within-group secular
trend in the initiation time or administered dose
of antivenom during the study period (data not
shown). The baseline characteristics of the 179
patients are summarized in Table 1.
Patients in the medical and surgical groups
were similar in many of their baseline character-
istics. Surgical group patients, however, received a
higher dose of antivenom, were more frequently
treated with antibiotics, and were more likely to
be hospitalized before the year 2001 (Table 1).
Table 2 presents the frequency of develop-
ing various outcomes among the 179 patients.
Eight patients (4 in each group) developed life-
threatening complications, but none died. Two
patients envenomed by Taiwan habu underwent
digit amputation due to severe gangrenous change.
The overall rate of positive skin test for antivenom
was 10% (17 patients). All of them received an-
tivenom after treatment with antihistamine and
dexamethasone, and none developed allergic reac-
tions. Antivenom-related allergic reactions were
recorded in six (3%) patients who tested negative.
Table 2 also shows the results of both univari-
ate and multivariate analyses. Using patients in the
medical group as the reference group, the crude
ORs of having life-threatening complications, other
complications, and adverse effects of antivenom
were all not different from unity. The ORs adjusted
for age, gender, calendar year of envenomation,
severity of envenomation, and use of antibiotics
again revealed no differences between the two
groups of inpatients. Further, none of the afore-
mentioned potential confounders was signifi-
cantly associated with the primary outcome. The
length of hospital stay was longer for surgical
group patients (7.7 ± 7.3 days) than for medical
group patients (5.9 ± 5.8 days), but the difference
was not significant (p = 0.07).
Discussion
In this study, both univariate and multivariate
analyses failed to show that a higher dose of an-
tivenom received by patients in the surgical group
(5.9 ± 4.2 vials) was superior to the dose recom-
mended by the PCC (2.7 ± 1.6 vials) in reducing
the major complications of crotaline snakebites.
Our finding is consistent with previous studies on
other snake antivenoms,7,10 and supports the PCC
approach for the management of Taiwan habu and
green habu snakebites.
Some major complications of snake envenoma-
tion, such as coagulopathy, may be reversed by
prompt administration of antivenom. A previous
randomized trial demonstrated that compared to a
high dose of antivenom, a lower dose can as effec-
tively correct coagulopathy in patients with Bothrops
envenomation.10 In this study, both high-dose
and low-dose antivenom therapy promptly cor-
rected coagulopathy, suggesting a threshold effect
of antivenom in the treatment of venom-related
coagulopathy. On the contrary, current published
data do not show any dose-related efficacy of an-
tivenom in preventing or treating myotoxicity and
nephrotoxicity from hemorrhagic snakebites.15
In this study, the higher dose of antivenom seemed
to be associated with a lower, albeit insignificant,
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Table 1. Baseline demographic and clinical characteristics of 179 patients with crotaline snakebites*
Surgical group (n = 89) Medical group (n = 90) p
Age (yr) 45.9 ± 20.5 44.4 ± 17.5 0.6
Male 64 (72) 59 (66) 0.4
Major comorbidities 2 (2) 1 (1) 0.6
Transfer from other hospitals 52 (58) 63 (70) 0.1
Prehospital management 12 (14) 17 (19) 0.4
Calendar year of envenomation 0.005
1991–1995 24 (27) 14 (16)
1996–2000 37 (42) 26 (29)
2001–2005 28 (32) 50 (56)
Snake species 1.0
Protobothrops mucrosquamatus 68 (76) 68 (76)
Trimeresurus stejnegeri stejnegeri 21 (24) 22 (24)
Site of snakebite 0.9
Upper limb 41 (46) 43 (48)
Lower limb 48 (54) 47 (52)
Acute symptoms/signs
Local pain 89 (100) 90 (100) 1.0
Inflammation 89 (100) 90 (100) 1.0
Local bleeding 20 (23) 19 (21) 0.9
Bruising 65 (73) 61 (68) 0.5
Blistering 15 (17) 12 (13) 0.5
Severity of envenomation† 0.5
Mild to moderate 49 (55) 48 (53)
Severe to very severe 40 (45) 42 (47)
Start of antivenom ≤ 8 hr 79 (89) 82 (91) 0.9
Antivenom dose (vials) 5.9 ± 4.2 2.7 ± 1.6 < 0.001
Route of antivenom 1.0
Intravenous infusion 84 (94) 84 (93)
Local injection plus intravenous 5 (6) 6 (7)
Use of antibiotics 83 (93) 54 (60) < 0.001
*Data are presented as mean ± standard deviation or n (%); †the original four categories of severity of envenomation were reclassified
into two categories of “mild to moderate” and “severe to very severe” because there were only two patients with mild envenomation and
three with very severe envenomation.
risk of mild-to-moderate rhabdomyolysis and
acute renal impairment. However, that treatment
was not more effective in preventing severe rhab-
domyolysis or renal failure. The length of hospi-
tal stay was also not shortened among patients in
the surgical group. Therefore, although a higher
dose of antivenom may be beneficial in prevent-
ing milder myotoxicity and renal impairment, its
clinical importance is probably limited.
Envenomation by Taiwan habu and green habu
can result in severe tissue damage, such as com-
partment syndrome. Antivenom is thus frequently
administered in the hope of ameliorating local
toxicity. However, limited published data are con-
troversial on what constitutes an efficacious dosage
of antivenom in preventing local edema and tis-
sue necrosis.15 The results of this study suggested
that a higher dose of antivenom was not more ef-
fective in abolishing local complications or re-
ducing the need for surgical treatment, a finding
consistent with a previous trial on equine F(ab’)2
antivenoms in Brazil.16
The incidence of adverse effects of antivenom is
likely to be an important factor in deciding whether
and how antivenom should be administered.
Equine-derived F(ab’)2 antivenoms produced in
other countries have various incidences of adverse
reactions, ranging from 4.3% in the French FAV-
African (highly purified equine F(ab’)2) anti-
venom to 53% in the Brazilian equine F(ab’)2
antivenom.17,18 Severe life-threatening reactions,
however, are rare.15 In this study, the incidence 
of adverse effects of antivenom was 3%, a result
consistent with previous reports in Taiwan.19,20
We also did not observe any patient who experi-
enced severe allergic reactions or serum sickness.
Moreover, a positive skin test did not predict the
occurrence of allergic reactions. The safety profile
and the discrepancy between skin test and allergic
reaction to the F(ab’)2 antivenom agrees with
Malasit et al’s proposition of possible obviation of
routine sensitivity test before antivenom therapy.21
This was a retrospective study. Therefore, the
identification and ascertainment of minor study
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Table 2. Outcomes of the 179 patients with crotaline snakebites and their association with treatment group
OR (95% CI)
Surgical group (n = 89) Medical group* (n = 90)
Crude Adjusted†
Life-threatening 4 (5) 4 (5) 1.0 (0.2–4.2) 1.4 (0.2–7.7)
complications‡
Other complications 28 (32) 35 (39) 0.7 (0.4–1.3) 0.5 (0.2–1.0)
Coagulopathy 4 (5) 5 (6) 0.8 (0.2–3.1) 0.8 (0.2–4.2)
Rhabdomyolysis 3 (3) 10 (11) 0.3 (0.1–1.1) 0.3 (0.1–1.2)
Acute renal impairment 1 (1) 4 (4) 0.2 (0–2.2) 0.1 (0–1.2)
Cellulitis/necrosis 17 (19) 21 (23) 0.8 (0.4–1.6) 0.5 (0.2–1.1)
Compartment syndrome 4 (5) 6 (7) 0.7 (0.2–2.4) 0.5 (0.1–1.9)
Dermatomy/fasciotomy 4 (5) 3 (3) 1.4 (0.3–6.3) 0.7 (0.1–4.2)
Skin graft 8 (9) 5 (6) 1.7 (0.5–5.3) 0.9 (0.2–3.2)
Digit amputation 1 (1) 1 (1) 1.0 (0.1–16.4) 0.4 (0–6.7)
Adverse effects of 3 (3) 3 (3) 1.0 (0.2–5.2) 1.3 (0.2–8.1)
antivenom
*Reference group; †adjusted for age, gender, calendar year of envenomation, severity of envenomation and use of antibiotics; ‡including
severe rhabdomyolysis (creatine phosphokinase ≥ 10,000 U/L) and acute renal failure (creatinine ≥ 3 mg/dL). OR = odds ratio; CI =
confidence interval.
outcomes may be incomplete. This could result
in an underestimation of the true incidence of
certain effects. However, the findings on major
and life-threatening complications were unlikely
to be biased. Nevertheless, because the number
of patients with life-threatening complications
was small in this study and because we did not
measure circulating venom levels, it remains pos-
sible that for a few severely envenomed patients,
a dose of antivenom that is higher than the PCC-
recommended dose may be beneficial.
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